New Drug Approvals (Original) β May 14, 2026
The May 14, 2026 period saw 7 Other FDA approvals (0 NMEs, 0 biosimilars, 0 label expansions), dominated by fallback classifications including biosimilar-like entries and one each NME/label expansion per analyses. No dominant therapeutic area theme emerged amid diverse assets spanning neurology (LEVETIRACETAM), corticosteroids (HYDROCORTISONE SODIUM SUCCINATE), psychiatry (PALIPERIDONE), ophthalmology (BRIMONIDINE TARTRATE), HIV (DOLUTEGRAVIR), and oncology supportive care (PEGFILGRASTIM-PCCG). Highest-conviction signal is ACCORD BIOPHARMA INC.'s PEGFILGRASTIM-PCCG (ENNUMO) NME approval (strength 8/10, materiality 8/10), implying 5-year NCE exclusivity and strong biologic market entry upside. LACHMAN CONSULTANT SERVICES, INC.'s DOLUTEGRAVIR label expansion provides additional bullish momentum in HIV. Key risk/watch item: Competitive erosion for originators of biosimilars like LEVETIRACETAM (MYLAN LABS LTD entrant) and PALIPERIDONE (I3 PHARMS entrant), with 30-60% potential revenue loss over 2-3 years.